bluebird bio Inc (BLUE) Shares Sold by Candriam Luxembourg S.C.A.
Candriam Luxembourg S.C.A. lessened its holdings in shares of bluebird bio Inc (NASDAQ:BLUE) by 27.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 42,000 shares of the biotechnology company’s stock after selling 16,000 shares during the period. Candriam Luxembourg S.C.A.’s holdings in bluebird bio were worth $7,480,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Meeder Asset Management Inc. lifted its position in shares of bluebird bio by 2,110.3% during the 4th quarter. Meeder Asset Management Inc. now owns 641 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 612 shares during the last quarter. NuWave Investment Management LLC acquired a new position in shares of bluebird bio during the 4th quarter worth about $135,000. Ladenburg Thalmann Financial Services Inc. lifted its position in shares of bluebird bio by 454.2% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock worth $136,000 after purchasing an additional 813 shares during the last quarter. QS Investors LLC lifted its position in shares of bluebird bio by 70.7% during the 2nd quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 500 shares during the last quarter. Finally, CIBC Asset Management Inc acquired a new position in shares of bluebird bio during the 4th quarter worth about $247,000.
In other news, COO Susanna Gatti High sold 1,282 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $172.15, for a total value of $220,696.30. Following the completion of the transaction, the chief operating officer now directly owns 13,718 shares of the company’s stock, valued at approximately $2,361,553.70. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Philip D. Gregory sold 2,250 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $172.54, for a total value of $388,215.00. Following the completion of the transaction, the insider now directly owns 28,734 shares of the company’s stock, valued at $4,957,764.36. The disclosure for this sale can be found here. Over the last three months, insiders sold 200,280 shares of company stock valued at $37,818,846. 3.90% of the stock is currently owned by insiders.
Several equities analysts recently weighed in on BLUE shares. Canaccord Genuity started coverage on bluebird bio in a research report on Tuesday, December 5th. They set a “buy” rating and a $202.00 price objective for the company. Maxim Group boosted their price objective on bluebird bio from $170.00 to $200.00 and gave the stock a “buy” rating in a research report on Thursday, November 30th. BTIG Research raised bluebird bio from a “neutral” rating to a “buy” rating and set a $177.00 price target for the company in a report on Thursday, November 2nd. BMO Capital Markets upped their price target on bluebird bio from $134.00 to $162.00 and gave the company a “buy” rating in a report on Monday, October 30th. Finally, SunTrust Banks upped their price target on bluebird bio from $108.00 to $163.00 and gave the company a “buy” rating in a report on Friday, November 3rd. Two analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $161.45.
COPYRIGHT VIOLATION NOTICE: “bluebird bio Inc (BLUE) Shares Sold by Candriam Luxembourg S.C.A.” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2018/02/15/bluebird-bio-inc-blue-shares-sold-by-candriam-luxembourg-s-c-a.html.
bluebird bio Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio Inc (NASDAQ:BLUE).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.